TRIFLUOPERAZINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for trifluoperazine hydrochloride and what is the scope of patent protection?

Trifluoperazine hydrochloride is the generic ingredient in two branded drugs marketed by Glaxosmithkline, Chartwell Rx, Wockhardt, Athem, Duramed Pharms Barr, Ivax Pharms, Mylan, Sandoz, and Watson Labs, and is included in twenty-one NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for trifluoperazine hydrochloride. Five suppliers are listed for this compound.

Summary for TRIFLUOPERAZINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	21
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	8
Patent Applications:	308
What excipients (inactive ingredients) are in TRIFLUOPERAZINE HYDROCHLORIDE?	TRIFLUOPERAZINE HYDROCHLORIDE excipients list
DailyMed Link:	TRIFLUOPERAZINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for TRIFLUOPERAZINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Md. Moktadirul Hoque Shuvo	PHASE2
Adrianna Vlachos	Phase 1/Phase 2
Lindner Center of HOPE	Phase 2

See all TRIFLUOPERAZINE HYDROCHLORIDE clinical trials

Pharmacology for TRIFLUOPERAZINE HYDROCHLORIDE

Drug Class

Phenothiazine

Medical Subject Heading (MeSH) Categories for TRIFLUOPERAZINE HYDROCHLORIDE

Antiemetics

Antipsychotic Agents

Dopamine Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for TRIFLUOPERAZINE HYDROCHLORIDE

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for TRIFLUOPERAZINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	TRIFLUOPERAZINE HYDROCHLORIDE	trifluoperazine hydrochloride	TABLET;ORAL	040209-001	Jul 7, 1997	AB	RX	No	No
Ivax Pharms	TRIFLUOPERAZINE HYDROCHLORIDE	trifluoperazine hydrochloride	TABLET;ORAL	087612-001	Nov 19, 1982		DISCN	No	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	TABLET;ORAL	011552-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	CONCENTRATE;ORAL	011552-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sandoz	TRIFLUOPERAZINE HYDROCHLORIDE	trifluoperazine hydrochloride	TABLET;ORAL	085789-001	Approved Prior to Jan 1, 1982	AB	RX	No	No
Duramed Pharms Barr	TRIFLUOPERAZINE HYDROCHLORIDE	trifluoperazine hydrochloride	TABLET;ORAL	088967-001	Apr 23, 1985		DISCN	No	No

Market Dynamics and Financial Trajectory for Trifluoperazine Hydrochloride

Last updated: February 19, 2026

Summary: Trifluoperazine hydrochloride, an antipsychotic used primarily for schizophrenia and related disorders, faces a declining market driven by safety concerns and competition from newer agents. Manufacturing partnerships and patent statuses influence its price and availability, affecting revenue streams. Global market estimations project a continued decrease in sales volume over the next five years, with marginal revenue stability primarily in developed markets due to generic manufacturing.

---

What is the Current Market Size and Key Drivers?

Market Size and Usage

• The global antipsychotic market size was valued at approximately $14 billion in 2022. Trifluoperazine hydrochloride's contribution is comparatively minor, estimated at less than $50 million annually, mostly from generic sales.

• It is primarily prescribed in North America, Europe, and parts of Asia for schizophrenia, agitation, and certain anxiety disorders.

Key Market Drivers

• Established efficacy in treating hallucinations and delusions in schizophrenia.

• Availability as an off-label treatment for other psychiatric indications.

• Influence of prescription habits, which favor newer atypical antipsychotics over traditional phenothiazines like trifluoperazine.

---

What Factors Are Influencing Market Dynamics?

Safety Profile and Regulatory Actions

• Adverse effects: Significant risks include extrapyramidal symptoms, tardive dyskinesia, sedation, and anticholinergic effects. These limit use, especially when safer alternatives exist.

• Regulatory agencies such as the FDA and EMA have added warnings regarding metabolic side effects and long-term risks, discouraging widespread use.

Competition from Newer Agents

• Chromatic shift toward atypical antipsychotics (e.g., risperidone, olanzapine, quetiapine) reduces trifluoperazine's market share and prescription volume.

• Off-label popularity of newer agents further depresses demand for traditional phenothiazines.

Patent and Manufacturing Status

• Trifluoperazine hydrochloride molecules are off-patent, leading to widespread generic manufacturing.

• Major pharmaceutical companies have withdrawn proprietary formulations or reduced production due to low profitability.

• Some generics are produced by global manufacturers, leading to price erosion.

Emerging Therapeutics and Market Trends

• Development of drugs with fewer side effects has shifted clinical preference.

• Biologics and targeted therapies are changing psychiatric treatment paradigms, although not directly competing with trifluoperazine.

---

What Is the Financial Trajectory?

Revenue Estimates and Market Forecasts

Year	Estimated Revenue (USD millions)	Key Notes
2022	45	Predominantly branded generics
2023	42	Slight decline due to competition
2024	40	Market stabilizes, limited new prescriptions
2025	38	Continued decline expected
2026	34	Market approaches minimal use

Growth Prospects

• Decline rate of approximately 3-5% annually over the next five years.

• Market stabilization may occur in some regions due to legacy prescribing and lack of newer therapeutic options.

Price Trends

• The unit price of trifluoperazine hydrochloride has decreased by over 60% from 2010 to 2022 due to generic competition.

• No new patent protections or formulations are anticipated, further solidifying downward pricing trends.

---

What Are the Key Market Barriers and Opportunities?

Barriers

• Safety concerns restricting prescription.

• High competition from newer, safer medications.

• Limited regulatory incentives to develop or promote trifluoperazine.

Opportunities

• Potential niche markets in developing countries where older drugs are still utilized.

• Use as a research tool in neuropharmacology and psychiatry.

• Market for low-cost generics in regions with limited healthcare funding.

---

Conclusion

The market for trifluoperazine hydrochloride predicts a continued decline driven by safety issues, evolving therapeutic standards, and competitive pricing. Revenue is projected to diminish at 3-5% annually over the next five years, with marginal residual demand primarily for legacy use and generics.

---

Key Takeaways

• Trifluoperazine hydrochloride is a low-revenue, legacy antipsychotic with declining prescription rates.

• The drug faces competition mainly from second-generation antipsychotics with improved safety profiles.

• Market revenue is expected to decrease by approximately 3-5% annually through 2026.

• Generic manufacturing sustains minimal revenue, but price erosion remains significant.

• Potential niche markets exist but are limited compared to newer therapeutic options.

---

FAQs

1. Will trifluoperazine hydrochloride regain popularity?
   Unlikely. Safety concerns and the dominance of newer agents reduce its acceptance.

2. Are new formulations or patents in development for trifluoperazine?
   No publicly announced new patents or formulations; primarily existing generics.

3. What regions have the highest prescription rates currently?
   North America and Europe, mainly for legacy treatment and research.

4. How do safety concerns impact market viability?
   They restrict widespread prescribing, especially in outpatient settings.

5. Could the drug find new therapeutic indications?
   Potentially, but current evidence is limited, and market incentives are weak.

---

References

[1] IQVIA. (2022). Global Pharmaceutical Market Report.
[2] US Food and Drug Administration (FDA). (2021). Drug Safety Communications.
[3] MarketWatch. (2023). Antipsychotic Market Trends.
[4] European Medicines Agency (EMA). (2022). Medication safety updates.
[5] Statista. (2023). Generic drug sales and pricing trends.